Longboat Clinical Ltd.

Based in Ireland, Longboat Clinical Ltd. specializes in clinical trial solutions, enhancing operational efficiency through its innovative technology that connects research sites with sponsors and Contract Research Organizations (CROs). Founded in 2014 and headquartered in Dublin, Ireland, Longboat Clinical Ltd. operates in the clinical research sector, providing advanced technological solutions to streamline study activation processes.

In November 2020, Longboat was acquired by Advarra, Inc. , a portfolio company of Genstar Capital Partners and Linden, which expanded its compliance management offerings. The founders and specific details of prior ventures are not publicly available. Longboat Clinical Ltd.

's core offering is its Study Collaboration Solution, a technology designed to improve coordination among research sites, sponsors, and CROs, facilitating faster site activation in clinical trials. This solution features Guided Site Journeys, allowing sites to track study activation tasks effectively while providing real-time updates to sponsors and CROs. The company serves over 225,000 researchers across North America, Europe, and Asia, including academic medical centers and health systems, aiming to reduce delays in clinical research processes. In 2023, Longboat Clinical Ltd.

reported a revenue of USD 18. 46 mn and an EBITDA of USD 6. 38 mn, reflecting its operational performance and subscription-based revenue model focused on clinical research collaborations. Longboat Clinical Ltd.

plans to leverage the acquisition by Advarra to enhance its product offerings and expand into new geographic markets. The integration will facilitate the development of new compliance management tools and connect existing resources for patient engagement. The strategic direction appears to focus on broadening the client base and enhancing technological capabilities, supported by insights from the recent acquisition on November 23, 2020.